Overview

*

net lossof $71.8 mln, or $0.83 per share, versus loss of $68.1 million, or $0.80 per share year ago

* Syndax Q2 Revuforj rev grows 43% compared with first quarter

* Niktimvo shows significant growth in first full quarter of U.S. launch

* Co holds $517.9 mln in cash, supporting path to profitability

Outlook

* Syndax expects stable expenses over the next few years

* Company anticipates reaching profitability with current cash reserves

* Syndax expects full-year 2025 operating expenses of $370 to $390 mln

* Company not providing revenue guidance at this time

Result Drivers

* REVUFORJ GROWTH - Revuforj net revenue rose 43% quarter-over-quarter, driven by deeper penetration into the KMT2A population and patient recontinuations post-transplant

* NIKTIMVO LAUNCH - Niktimvo achieved significant revenue growth in its first full quarter of U.S. launch, contributing to profitability

* STABLE EXPENSES - Syndax expects stable expenses over the next few years, aiding its path to profitability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.83

Q2 Net -$71.85

Income mln

Q2 Cash $517.90

& mln

Investme

nts

Q2 $107.31

Operatin mln

g

Expenses

Q2 -$69.35

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc ( SNDX ) is $33.50, about 70.2% above its August 1 closing price of $9.98

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)